PharmaMar
Manufacturing · Spain · 501-1,000 Employees
View Company Info for Free
Overview
Headquarters
Avda. De Los Reyes 1pol, Colmenar Viejo,...Phone Number
+34 918466000Website
www.pharmamar.comRevenue
$171.4 MillionStock Symbol
PHMIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
1
1
1
1
1
1
About PharmaMar
Founded in 1986, PharmaMar a biopharmaceutical company, engages in the research, development, production, and commercialization of bio-active principles of marine origin for use in oncology in Spain, the rest of Europe, and internationally. The company operates through three segments: Oncology, Diagnostics, and RNA interference. It develops and commercializes Yondelis for the treatment of soft tissue sarcomas and ovarian cancer; and Aplidin for treating multiple myeloma. The company also develops clinical-stage programs, including Lurbinectedin, PM184, and PM14. Also, it develops and markets diagnostics kits; and develops drugs with therapeutic activity based on reducing or silencing gene expression. The company is headquartered in Madrid, Spain.Explore more
PharmaMar Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is PharmaMar your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Product Launch: Get notified when PharmaMar launches new products
Check if PharmaMar has recently received funding, and reach out quickly before it becomes old news!
Earning: See what the market has to say on PharmaMar recently announced quarterly report
Check out if PharmaMar is spiking on competitors!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Website visits: Recent activity has been detected on your website
Funding: Get notified immidiatlly once PharmaMar has new funding data
Congratulate Masked Content for being promoted to Masked Content at PharmaMar
Click to see if PharmaMar had a recent Job posting/layoffs
PharmaMar, which may be a good buyer, showed buying intent in Masked Content Topic
Recommended Actions
Find VP level buyers at PharmaMar
Find 2 more new buyers
Company Profile Activity
Activity Insights
PharmaMar is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
PharmaMar is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about PharmaMar.
PharmaMar Tech Stack
A closer look at the technologies used by PharmaMar
See more technologies
Most Recent Scoops
Earnings
PharmaMar has reported positive operating cash flow of 11.9 million for the first half of 2026, with net cash of 126.4 million at the end of June 2026, representing a 4% increase compared to December 31, 2025, and debt reduced to 43 million, 8% lower than at year-end 2025.
Earnings, Business Finance, Finance, Financing & Debt
Project
PharmaMar has announced plans to begin a PM54 platform trial in Q4 of the current year, with centers in Europe and the USA, investigating different doses, dosing regimens, indications, and combinations, with the goal of initiating one or more registration trials by 2028 or 2029.
Medical Research, Clinical Operations
Project
PharmaMar has announced that the SALUTO trial is fully enrolled, with data expected to be available in the first half of 2027, investigating lurbinectedin in leiomyosarcoma, an indication where the potential number of treatment cycles could be approximately double that observed in small cell lung cancer based on prior study results.
Medical Research, Clinical Operations
Project
PharmaMar has announced that 120 patients have been enrolled in solid tumor trials for PM54, with encouraging early results observed in head and neck, esophagus, lung, and sarcomas, and first clinical data expected to be presented at ESMO for the first Phase 1 dose range cohorts, with broader clinical data anticipated in 2027.
Medical Research, Pharmaceuticals, Clinical Operations
Project
Laboratory Operations, Medical Research, Clinical Operations
PharmaMar News & Media
PharmaMar looks to accelerate oncology research with AI through collaboration with Globant
The new alliance has launched a multi-agent AI framework to support faster, data-driven decisions in cancer research. Agentic AI system achieves 15x faster insights with over 90% accuracy. MADRID, March 19, 2026 /PRNewswire/ -- Globant (NYSE: GLOB), a digitally native company that helps...PharmaMar presents at ASCO that the Zepzelca®(lurbinectedin) and atezolizumab (Tecentriq®) combination significantly improves survival as first-line maintenance therapy for extensive-stage small cell lung cancer
First-line maintenance combination therapy reduced the risk of disease progression or death by 46%, with a median overall survival of 13.2 months vs 10.6 months for atezolizumab alone from the point of randomization First Phase 3 study to demonstrate statistically significant and...PharmaMar Announces Positive and Statistically Significant Overall Survival and Progression-Free Survival Results for Zepzelca® (lurbinectedin) and Atezolizumab Combination in First-Line Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer
Jazz plans to submit supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) and PharmaMar will submit Marketing Authorisation Application (MAA) to the European Medicines Agency (EMA) in first half of the year 2025 for this combination therapy as a...Spanish Pharma Companies Boost Profits to Over 150 Million Euros by June - Born2Invest
According to the results presented by the pharmaceutical giants to the National Securities Commission (CNMV), the revenues of these five companies also rose in the first half of the year, although with a more moderate growth than profits. Rovi was the only listed Spanish pharmaceutical company to see its revenues fall in the first six months, recording a year-on-year drop of 13.5%.
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding PharmaMar
Sign Up For FreeTo access detailed company insights
Founded in 1986, PharmaMar a biopharmaceutical company, engages in the research, development, production, and commercialization of bio-active principles of marine origin for use in oncology in Spain, the rest of Europe, and internationally. The company operates through three segments: Oncology, Diagnostics, and RNA interference. It develops and com... Read More
